Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 4
2004 4
2005 6
2006 4
2007 5
2008 3
2009 2
2010 13
2011 10
2012 5
2013 9
2014 7
2015 7
2016 4
2017 7
2018 3
2019 9
2020 5
2021 9
2022 12
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors.
Anthiya S, Öztürk SC, Yanik H, Tavukcuoglu E, Şahin A, Datta D, Charisse K, Álvarez DM, Loza MI, Calvo A, Sulheim E, Loevenich S, Klinkenberg G, Schmid R, Manoharan M, Esendağlı G, Alonso MJ. Anthiya S, et al. Among authors: calvo a. J Control Release. 2023 May;357:67-83. doi: 10.1016/j.jconrel.2023.03.016. Epub 2023 Mar 28. J Control Release. 2023. PMID: 36921725 Free article.
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.
Monteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, de Pablos-Aragoneses A, Yebra N, Retana D, Baena P, Fustero-Torre C, Graña-Castro O, Troulé K, Caleiras E, Tezanos P, Muela P, Cintado E, Trejo JL, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Lain A, Mazarico Gallego J, Ferrer I, Suárez R, Garrido-Martín EM, Paz-Ares L, Dalmasso C, Cohen-Jonathan Moyal E, Siegfried A, Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, Bertero L, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martin SM, Gonzalez A, Adler O, Erez N; RENACER; Valiente M. Monteiro C, et al. Among authors: calvo a. Nat Med. 2022 Apr;28(4):752-765. doi: 10.1038/s41591-022-01749-8. Epub 2022 Apr 11. Nat Med. 2022. PMID: 35411077 Free PMC article.
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer.
Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. Moutafi MK, et al. Among authors: calvo a. J Immunother Cancer. 2022 Aug;10(8):e004757. doi: 10.1136/jitc-2022-004757. J Immunother Cancer. 2022. PMID: 36002182 Free PMC article.
PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A. Exposito F, et al. Among authors: calvo a. Cancer Res. 2023 Aug 1;83(15):2513-2526. doi: 10.1158/0008-5472.CAN-22-3023. Cancer Res. 2023. PMID: 37311042
Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.
Anfray C, Mainini F, Digifico E, Maeda A, Sironi M, Erreni M, Anselmo A, Ummarino A, Gandoy S, Expósito F, Redrado M, Serrano D, Calvo A, Martens M, Bravo S, Mantovani A, Allavena P, Andón FT. Anfray C, et al. Among authors: calvo a. J Immunother Cancer. 2021 Sep;9(9):e002408. doi: 10.1136/jitc-2021-002408. J Immunother Cancer. 2021. PMID: 34531246 Free PMC article.
YES1 Is a Druggable Oncogenic Target in SCLC.
Redin E, Garrido-Martin EM, Valencia K, Redrado M, Solorzano JL, Carias R, Echepare M, Exposito F, Serrano D, Ferrer I, Nunez-Buiza A, Garmendia I, García-Pedrero JM, Gurpide A, Paz-Ares L, Politi K, Montuenga LM, Calvo A. Redin E, et al. Among authors: calvo a. J Thorac Oncol. 2022 Dec;17(12):1387-1403. doi: 10.1016/j.jtho.2022.08.002. Epub 2022 Aug 18. J Thorac Oncol. 2022. PMID: 35988891 Free article.
Molecular biomarkers in early stage lung cancer.
Rodríguez M, Ajona D, Seijo LM, Sanz J, Valencia K, Corral J, Mesa-Guzmán M, Pío R, Calvo A, Lozano MD, Zulueta JJ, Montuenga LM. Rodríguez M, et al. Among authors: calvo a. Transl Lung Cancer Res. 2021 Feb;10(2):1165-1185. doi: 10.21037/tlcr-20-750. Transl Lung Cancer Res. 2021. PMID: 33718054 Free PMC article. Review.
YES1: A Novel Therapeutic Target and Biomarker in Cancer.
Garmendia I, Redin E, Montuenga LM, Calvo A. Garmendia I, et al. Among authors: calvo a. Mol Cancer Ther. 2022 Sep 6;21(9):1371-1380. doi: 10.1158/1535-7163.MCT-21-0958. Mol Cancer Ther. 2022. PMID: 35732509 Review.
125 results